文献速递妇科肿瘤

紫杉醇、顺铂与维利帕尼治疗持续性或复发性宫颈癌的I期试验:一项NRG肿瘤学研究(NCT#01281852)

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
PubMed 文献 · Ann Oncol · 2017-01-01

这项I期试验在持续性或复发性宫颈癌患者中评估PARP抑制剂维利帕尼联合紫杉醇和顺铂的最大耐受剂量。34例患者接受治疗,400 mg剂量组6例中1例出现剂量限制性毒性,最大耐受剂量未达到。全组客观缓解率34%,400 mg组为60%,中位无进展生存期6.2个月,总生存期14.5个月。作者结论为联合方案安全可行。

要点

  • 维利帕尼联合紫杉醇和顺铂的I期剂量递增试验中,最大耐受剂量未达到。
  • 29例可测量病灶患者客观缓解率为34%(95%CI 20%-53%),400 mg组为60%(n=3/5,95%CI 23%-88%)。
  • 中位无进展生存期6.2个月(95%CI 2.9-10.1),总生存期14.5个月(95%CI 8.2-19.4)。

核心结论

  • 维利帕尼联合紫杉醇和顺铂作为持续性或复发性宫颈癌患者的一线治疗是安全且可行的。

研究设计与样本

  • I期剂量递增试验采用标准3+3设计,入组持续性或复发性宫颈癌且不适合根治性治疗的患者。
  • 患者须接受过同步放化疗及可能的巩固化疗,并具有足够的器官功能。
  • 给药方案为第1天紫杉醇175 mg/m2、第2天顺铂50 mg/m2,维利帕尼50至400 mg口服每日两次第1-7天,每21天一个周期直至进展。
  • 剂量限制性毒性在第一周期评估,共34例患者接受治疗。

主要发现

  • 剂量限制性毒性(n=1)包括4级呼吸困难、持续≥3周的3级中性粒细胞减少和发热性中性粒细胞减少。
  • 400 mg剂量组6例中1例出现剂量限制性毒性,最大耐受剂量未达到。
  • 29例可测量病灶患者客观缓解率为34%(95%CI 20%-53%),400 mg剂量组为60%(n=3/5,95%CI 23%-88%)。
  • 中位无进展生存期6.2个月(95%CI 2.9-10.1),中位总生存期14.5个月(95%CI 8.2-19.4)。
  • FANCD2 foci阴性或异质性占31%,阳性占69%,客观缓解率与FANCD2 foci无关联(P=0.53)。

临床怎么用

  • 原文结论为维利帕尼联合紫杉醇和顺铂作为持续性或复发性宫颈癌患者的一线治疗是安全且可行的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical studies demonstrate poly(ADP-ribose) polymerase (PARP) inhibition augments apoptotic response and sensitizes cervical cancer cells to the effects of cisplatin. Given the use of cisplatin and paclitaxel as first-line treatment for persistent or recurrent cervical cancer, we aimed to estimate the maximum tolerated dose (MTD) of the PARP inhibitor veliparib when added to chemotherapy. PATIENTS AND METHODS: Women with persistent or recurrent cervical carcinoma not amenable to curative therapy were enrolled. Patients had to have received concurrent chemotherapy and radiation as well as possible consolidation chemotherapy; have adequate organ function. The trial utilized a standard 3 + 3 phase I dose escalation with patients receiving paclitaxel 175 mg/m2 on day 1, cisplatin 50 mg/m2 on day 2, and escalating doses of veliparib ranging from 50 to 400 mg orally two times daily on days 1-7. Cycles occurred every 21 days until progression. Dose-limiting toxicities (DLTs) were assessed at first cycle. Fanconi anemia complementation group D2 (FANCD2) foci was evaluated in tissue specimens as a biomarker of response. RESULTS: Thirty-four patients received treatment. DLTs (n = 1) were a grade 4 dyspnea, a grade 3 neutropenia lasting ≥3 weeks, and febrile neutropenia. At 400 mg dose level (DL), one of the six patients had a DLT, so the MTD was not reached. Across DLs, the objective response rate (RR) for 29 patients with measurable disease was 34% [95% confidence interval (CI), 20%-53%]; at 400 mg DL, the RR was 60% (n = 3/5; 95% CI, 23%-88%). Median progression-free survival was 6.2 months (95% CI, 2.9-10.1), and overall survival was 14.5 months (95% CI, 8.2-19.4). FANCD2 foci was negative or heterogeneous in 31% of patients and present in 69%. Objective RR were not associated with FANCD2 foci (P = 0.53). CONCLUSIONS: Combining veliparib with paclitaxel and cisplatin as first-line treatment for persistent or recurrent cervical cancer patients is safe and feasible. CLINICAL TRIAL INFORMATION: NCT01281852.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Thaker PH, Salani R, Brady WE, et al. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol. 2017. PMID: 27998970. doi:10.1093/annonc/mdw635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。